Logo image of LBPH

Longboard Pharmaceuticals Inc (LBPH) Stock Fundamental Analysis

NASDAQ:LBPH - Nasdaq - US54300N1037 - Common Stock - Currency: USD

59.98  +0.02 (+0.03%)

After market: 60.01 +0.03 (+0.05%)

Fundamental Rating

3

Overall LBPH gets a fundamental rating of 3 out of 10. We evaluated LBPH against 195 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for LBPH as it has an excellent financial health rating, but there are worries on the profitability. LBPH has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LBPH had negative earnings in the past year.
LBPH had a negative operating cash flow in the past year.
LBPH Yearly Net Income VS EBIT VS OCF VS FCFLBPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

With a Return On Assets value of -25.70%, LBPH perfoms like the industry average, outperforming 59.38% of the companies in the same industry.
LBPH has a better Return On Equity (-27.74%) than 67.71% of its industry peers.
Industry RankSector Rank
ROA -25.7%
ROE -27.74%
ROIC N/A
ROA(3y)-65.03%
ROA(5y)N/A
ROE(3y)-77.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LBPH Yearly ROA, ROE, ROICLBPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

LBPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LBPH Yearly Profit, Operating, Gross MarginsLBPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, LBPH has more shares outstanding
LBPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LBPH Yearly Shares OutstandingLBPH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 5M 10M 15M 20M
LBPH Yearly Total Debt VS Total AssetsLBPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 63.60 indicates that LBPH is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 63.60, LBPH belongs to the top of the industry, outperforming 96.88% of the companies in the same industry.
There is no outstanding debt for LBPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 63.6
ROIC/WACCN/A
WACCN/A
LBPH Yearly LT Debt VS Equity VS FCFLBPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 15.97 indicates that LBPH has no problem at all paying its short term obligations.
LBPH's Current ratio of 15.97 is amongst the best of the industry. LBPH outperforms 88.54% of its industry peers.
A Quick Ratio of 15.97 indicates that LBPH has no problem at all paying its short term obligations.
LBPH has a Quick ratio of 15.97. This is amongst the best in the industry. LBPH outperforms 88.54% of its industry peers.
Industry RankSector Rank
Current Ratio 15.97
Quick Ratio 15.97
LBPH Yearly Current Assets VS Current LiabilitesLBPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.85% over the past year.
EPS 1Y (TTM)7.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, LBPH will show a small growth in Earnings Per Share. The EPS will grow by 2.83% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y4.61%
EPS Next 2Y-10.02%
EPS Next 3Y-10.5%
EPS Next 5Y2.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LBPH Yearly Revenue VS EstimatesLBPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
LBPH Yearly EPS VS EstimatesLBPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LBPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LBPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LBPH Price Earnings VS Forward Price EarningsLBPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LBPH Per share dataLBPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A cheap valuation may be justified as LBPH's earnings are expected to decrease with -10.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.02%
EPS Next 3Y-10.5%

More info and screens

0

5. Dividend

5.1 Amount

LBPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Longboard Pharmaceuticals Inc

NASDAQ:LBPH (11/29/2024, 7:46:54 PM)

After market: 60.01 +0.03 (+0.05%)

59.98

+0.02 (+0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners101.95%
Inst Owner Change-4.09%
Ins Owners0.04%
Ins Owner Change-2309.15%
Market Cap2.34B
Analysts75.38
Price Target65.96 (9.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.68%
Min EPS beat(2)-24.62%
Max EPS beat(2)-6.75%
EPS beat(4)1
Avg EPS beat(4)-4.45%
Min EPS beat(4)-24.62%
Max EPS beat(4)15.33%
EPS beat(8)4
Avg EPS beat(8)1.23%
EPS beat(12)5
Avg EPS beat(12)-2.26%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.18%
EPS NQ rev (1m)-1.15%
EPS NQ rev (3m)-24.01%
EPS NY rev (1m)-1.17%
EPS NY rev (3m)-7.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.51
P/tB 8.51
EV/EBITDA N/A
EPS(TTM)-2.23
EYN/A
EPS(NY)-2.88
Fwd EYN/A
FCF(TTM)-1.69
FCFYN/A
OCF(TTM)-1.69
OCFYN/A
SpS0
BVpS7.05
TBVpS7.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.7%
ROE -27.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.03%
ROA(5y)N/A
ROE(3y)-77.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.97
Quick Ratio 15.97
Altman-Z 63.6
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.55%
EPS Next Y4.61%
EPS Next 2Y-10.02%
EPS Next 3Y-10.5%
EPS Next 5Y2.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-65.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-67.64%
EBIT Next 3Y-40.09%
EBIT Next 5Y22.5%
FCF growth 1Y-93.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-93.52%
OCF growth 3YN/A
OCF growth 5YN/A